1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12-Pentacosafluorododecane | 66563-68-6

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12-Pentacosafluorododecane
• CAS: 66563-68-6
• 化学式: C₁₂HF₂₅
• 分子量: 620.1
• InChiKey: PLYVHXBRPARTON-UHFFFAOYSA-N

物化性质

• 沸点：
  205℃
• 密度：
  1.704
• 闪点：
  82℃

计算性质

• 辛醇/水分配系数(LogP)：
  8.9
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  25

反应信息

• 作为产物：
  描述：

  1-碘全氟十二烷 、 碳酸氢钠 生成 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12-Pentacosafluorododecane
  参考文献：
  名称：

  HUANG BING-NAN; HAAS A.; LIEB M., J. FLUOR. CHEM., 36,(1987) N 1, 49-62

  摘要：

  DOI：

文献信息

• Halogen substituted metallocene compounds for olefin polymerization
  申请人：Voskoboynikov Z. Alexander

  公开号：US20070135594A1

  公开（公告）日：2007-06-14

  A metallocene compound is represented by the formula (1): AMX n-1 wherein M is a transition metal atom having a coordination number of n selected from Group 3, 4, 5 or 6 of the Periodic Table of Elements, or a lanthanide metal atom, or actinide metal atom; A is a substituted monocyclic or polycyclic arenyl ligand pi-bonded to M, wherein said arenyl ligand includes at least one halogen substituent directly bonded to any sp 2 carbon atom at a bondable ring position of the ligand; and the or each X is a univalent anionic ligand, or two X are joined and bound to the metal atom to form a metallocycle ring, or two X are joined to form a chelating ligand, a diene ligand, or an alkylidene ligand.

  一种金属烯化合物可以用公式(1)表示： AMX n-1 其中，M是具有配位数n的过渡金属原子，选自元素周期表第3、4、5或6族，或为镧系金属原子，或锕系金属原子；A是与M以π键结合的取代的单环或多元环芳基配体，其中所述芳基配体包括至少一个直接键合到配体的可键合环位上的任意sp2碳原子上的卤素取代基；而X是单价阴离子配体，或者两个X连接并与金属原子结合形成一个金属环烯环，或者两个X连接形成一个螯合配体、二烯配体或烷基亚烯配体。
• [EN] SUBSTITUTED N-ALKYLPYRIMIDINONES<br/>[FR] N-ALKYLPYRIMIDINONES SUBSTITUES
  申请人：PHARMACIA & UPJOHN CO LLC

  公开号：WO2006040666A1

  公开（公告）日：2006-04-20

  This invention is directed generally to substituted pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such substituted pyrimidinone include compounds generally corresponding in structure to the following formula (I): wherein R1, R2, R3, R4A, R4B, R4C, R4D and R4E are as defined in this specification. This invention also is directed to compositions of such substituted pyrimidinones (particularly pharmaceutical compositions), intermediates for the syntheses of such substituted pyrimidinones, methods for making such substituted pyrimidinones, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.

  本发明一般涉及取代吡啶酮化合物，这些化合物通常抑制p38激酶、肿瘤坏死因子（TNF）和/或环氧合酶活性。这类取代吡啶酮包括与以下公式（I）结构相对应的化合物：其中R1、R2、R3、R4A、R4B、R4C、R4D和R4E按本说明书定义。本发明还涉及这些取代吡啶酮的组成物（特别是药物组成物）、用于合成这些取代吡啶酮的中间体、制造这些取代吡啶酮的方法，以及用于治疗（包括预防）与p38激酶活性、TNF活性和/或环氧合酶-2活性相关的病症（通常是病理状况）的方法。
• Method for Producing Compound Containing BIS (Perfluoroalkylsulfonyl) Methyl Group and Salt Thereof, and Solid Electrolyte Membrane Produced Using Same
  申请人：CENTRAL GLASS COMPANY, LIMITED

  公开号：US20150266816A1

  公开（公告）日：2015-09-24

  [Problem] To provide a method for producing a compound having a bis(trifluoroalkanesulfonyl)methyl group, which is a compound having a high acidity degree and hydrophobicity and useful as a raw material compound for a resin, and a salt thereof in a simple manner. [Solution] A method for producing a compound containing a bis(perfluoroalkylsulfonyl)methyl group and represented by the following formula and a salt of the compound. (Rf represents a perfluoroalkyl group having 1 to 12 carbon atoms. A represents a monovalent organic group. Y represents a single bond or a C 1 -C 4 linear, C 3 -C 4 branched or C 3 -C 4 cyclic alkylene group wherein each of some or all of hydrogen atoms may be substituted with a fluorine atom, a chlorine atom, a bromine atom or an iodine atom and an ether bond or an ester bond may be contained.)

  提供一种简单的方法，用于生产具有高酸度和疏水性的双(三氟烷磺酰基)甲基基团的化合物，该化合物可作为树脂的原料化合物，并提供该化合物的盐。生产含有双(全氟烷基磺酰基)甲基基团的化合物及其盐的方法如下所示： （Rf代表具有1至12个碳原子的全氟烷基基团。A代表一价有机基团。Y代表单键或C1-C4线性、C3-C4支链或C3-C4环烷基基团，其中部分或全部氢原子可被氟原子、氯原子、溴原子或碘原子取代，并且可能包含醚键或酯键。）
• Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
  申请人：Barta E. Thomas

  公开号：US20050009838A1

  公开（公告）日：2005-01-13

  This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A 1 , A 2 , Y, E 1 , E 2 , E 3 , and R x are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.

  这项发明通常涉及蛋白酶抑制剂（也称为“蛋白酶”），更具体地涉及对哌啶基和哌嗪基磺酰甲基羟肟酸的抑制作用，其中包括抑制基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或聚集素酶活性。这些羟肟酸通常在结构上对应于以下公式： （其中A 1 ，A 2 ，Y，E 1 ，E 2 ，E 3 和R x 如本说明书中所定义），并进一步包括这些化合物的盐。这项发明还涉及这些羟肟酸的组合物，合成这些羟肟酸的中间体，制备这些羟肟酸的方法，以及治疗与MMP活性和/或聚集素酶活性相关的病症（特别是病理性病症）的方法。
• Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
  申请人：McDonald J. Joseph

  公开号：US20050209278A1

  公开（公告）日：2005-09-22

  This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A 1 , A 2 , Y, E 1 , E 2 , E 3 , and R x are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.

  这项发明通常涉及蛋白酶抑制剂（也称为“蛋白酶”），更具体地涉及哌啶基和哌嗪基磺酰甲基羟肟酸，该类化合物在结构上抑制基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或聚集素酶活性。这类羟肟酸通常对应以下结构式： （其中A1、A2、Y、E1、E2、E3和Rx如本说明书中所定义），还包括这类化合物的盐。这项发明还涉及这类羟肟酸的组合物、合成这类羟肟酸的中间体、制备这类羟肟酸的方法，以及治疗与MMP活性和/或聚集素酶活性相关的疾病（特别是病理性疾病）的方法。